Match!

Deconstructing the neurobiology of cannabis use disorder.

Published on Apr 6, 2020in Nature Neuroscience21.126
· DOI :10.1038/S41593-020-0611-0
Jacqueline-Marie N. Ferland1
Estimated H-index: 1
(ISMMS: Icahn School of Medicine at Mount Sinai),
Yasmin L. Hurd61
Estimated H-index: 61
(ISMMS: Icahn School of Medicine at Mount Sinai)
Abstract
There have been dramatic changes worldwide in the attitudes toward and consumption of recreational and medical cannabis. Cannabinoid receptors, which mediate the actions of cannabis, are abundantly expressed in brain regions known to mediate neural processes underlying reward, cognition, emotional regulation and stress responsivity relevant to addiction vulnerability. Despite debates regarding potential pathological consequences of cannabis use, cannabis use disorder is a clinical diagnosis with high prevalence in the general population and that often has its genesis in adolescence and in vulnerable individuals associated with psychiatric comorbidity, genetic and environmental factors. Integrated information from human and animal studies is beginning to expand insights regarding neurobiological systems associated with cannabis use disorder, which often share common neural characteristics with other substance use disorders, that could inform prevention and treatment strategies. The increasing use of cannabis has brought significant attention to cannabis use disorder (CUD) and its neurobiological underpinnings. Here Ferland and Hurd discuss risk factors related to the development of CUD its neurobiological characteristics.
  • References (148)
  • Citations (1)
📖 Papers frequently viewed together
7 Citations
1 Citations
30 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References148
Newest
#1Eun-Kyung Hwang (NIDA: National Institute on Drug Abuse)H-Index: 1
#2Carl R. Lupica (NIDA: National Institute on Drug Abuse)H-Index: 38
Abstract Background The decriminalization and legalization of cannabis and the expansion of availability of medical cannabis in North America have led to an increase in cannabis use and the availability of high-potency strains. Cannabis potency is determined by the concentration of Δ9-tetrahydrocannabinol (Δ9-THC), a psychoactive constituent that activates cannabinoid CB1 and CB2 receptors. The use of high-potency cannabis is associated with cannabis use disorder and increased susceptibility to ...
Source
#1Kelly A. Sagar (BU: Boston University)H-Index: 7
#2Staci A. Gruber (Harvard University)H-Index: 39
2 CitationsSource
#1Ditte Demontis (Lundbeck)H-Index: 15
#2Veera M. Rajagopal (Lundbeck)H-Index: 2
Last. Anders D. Børglum (Lundbeck)H-Index: 44
view all 30 authors...
Cannabis is the most frequently used illicit psychoactive substance worldwide; around one in ten users become dependent. The risk for cannabis use disorder (CUD) has a strong genetic component, with twin heritability estimates ranging from 51 to 70%. Here we performed a genome-wide association study of CUD in 2,387 cases and 48,985 controls, followed by replication in 5,501 cases and 301,041 controls. We report a genome-wide significant risk locus for CUD (P = 9.31 × 10−12) that replicates in an...
5 CitationsSource
#1M. Di Forti (Mental Health Foundation)H-Index: 36
#2Diego Quattrone (Mental Health Foundation)H-Index: 10
Last. Elsje van der VenH-Index: 8
view all 87 authors...
Summary Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. Methods We included patients aged 18–64 years who presented to psychiatric services in 11 sites across E...
47 CitationsSource
#1Michael L. MillerH-Index: 10
#2Benjamin ChadwickH-Index: 4
Last. Yasmin L. Hurd (Allen Institute for Brain Science)H-Index: 61
view all 12 authors...
Neuronal circuits within the prefrontal cortex (PFC) mediate higher cognitive functions and emotional regulation that are disrupted in psychiatric disorders. The PFC undergoes significant maturation during adolescence, a period when cannabis use in humans has been linked to subsequent vulnerability to psychiatric disorders such as addiction and schizophrenia. Here, we investigated in a rat model the effects of adolescent exposure to Δ9-tetrahydrocannabinol (THC), a psychoactive component of cann...
4 CitationsSource
#1Bradley T. Kerridge (NIH: National Institutes of Health)H-Index: 4
#2S. Patricia Chou (NIH: National Institutes of Health)H-Index: 37
Last. Deborah S. Hasin (Columbia University)H-Index: 88
view all 11 authors...
Abstract To present nationally representative data on changes in the prevalences of 12-month cocaine use, cocaine use disorder (CocUD) and 12-month CocUD among 12-month cocaine users between 2001 and 2002 and 2012–2013. Data were derived from the 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) and the 2012–2013 NESARC-III. Between 2001 and 2002 and 2012–2013, prevalences of 12-month cocaine use and DSM-IV CocUD significantly increased and 12-month CocUD among 1...
7 CitationsSource
#1Marco Colizzi (South London and Maudsley NHS Foundation Trust)H-Index: 13
#2Nathalie Weltens (Katholieke Universiteit Leuven)H-Index: 7
Last. Sagnik Bhattacharyya (South London and Maudsley NHS Foundation Trust)H-Index: 33
view all 7 authors...
The neurobiological mechanisms underlying the association between cannabis use and acute or long-lasting psychosis are not completely understood. While some evidence suggests altered striatal dopamine may underlie the association, direct evidence that cannabis use affects either acute or chronic striatal dopamine is inconclusive. In contrast, pre-clinical research suggests that cannabis may affect dopamine via modulation of glutamate signaling. A double-blind, randomized, placebo-controlled, cro...
7 CitationsSource
#1Suman Chandra (University of Mississippi)H-Index: 21
#2Mohamed M. Radwan (University of Mississippi)H-Index: 21
Last. Mahmoud A. ElSohly (University of Mississippi)H-Index: 44
view all 6 authors...
Through the potency monitoring program at the University of Mississippi supported by National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations have been analyzed over the last decade, using a validated GC/FID method. The samples are classified as sinsemilla, marijuana, ditchweed, hashish, and hash oil (now referred to as cannabis concentrate). The number of samples received over the last 5 years has decreased dramatically due to the legalization of marijuana eith...
23 CitationsSource
#1Scott Mackey (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 7
#2Nicholas Allgaier (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 6
Last. Hugh Garavan (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 68
view all 61 authors...
Objective:Although lower brain volume has been routinely observed in individuals with substance dependence compared with nondependent control subjects, the brain regions exhibiting lower volume hav...
10 CitationsSource
Abstract What the cerebellum does to sensorimotor and vestibular control, it also does to cognition, emotion, and autonomic function. This hypothesis is based on the theories of dysmetria of thought and the universal cerebellar transform, which hold that the cerebellum maintains behavior around a homeostatic baseline, automatically, without conscious awareness, informed by implicit learning, and performed according to context. Functional topography within the cerebellum facilitates the modulatio...
483 CitationsSource
Cited By1
Newest
#1Daniel Feingold (Ariel University)H-Index: 8
#2Silviu BrilH-Index: 1
Last. Shaul Lev-Ran (TAU: Tel Aviv University)H-Index: 14
view all 5 authors...
Abstract Background The use of medical marijuana (MM) for the treatment of chronic pain is rapidly growing in the United States and Europe; however there is concern regarding the specificity of its therapeutic effects and the motivation underlying its use. While research indicates that among chronic pain prescribed opioids, depression has been associated with increased opioid dosage (regardless of pain levels), the extent to which depression and pain each contribute to MM dose among chronic pain...
Source